Amgen Inc., the world's biggest biotechnology company by sales, reached its highest value after announcing a restructuring plan that focuses on drugs approaching market approval. Amgen climbed 5.43 percent to close at $130.01 in New York, the highest share value since the company's initial public offering in 1983, according to data compiled by Bloomberg.